PT-141 (Bremelanotide / Vyleesi)

Definition

PT-141, now approved as bremelanotide (Vyleesi), is a melanocortin receptor agonist — it works on MC3-R and MC4-R receptors in the central nervous system to enhance sexual desire and arousal, completely independently of sex hormone levels. This central mechanism makes it unique: it affects libido through brain signaling rather than through hormonal pathways. FDA-approved (2019) for premenopausal women with HSDD — generalized, acquired low sexual desire that causes personal distress and is not explained by relationship issues or other medical conditions. It is administered as a subcutaneous injection 45 minutes before anticipated sexual activity, on an as-needed basis. Common side effects include nausea, flushing, and transient blood pressure changes. It is not currently FDA-approved for postmenopausal women, though off-label discussion with providers is possible.

Frequently Asked Question

How is PT-141 different from hormone therapy for low libido?

Hormone therapy (testosterone, estrogen) addresses the hormonal contributors to low libido. PT-141 (bremelanotide) works centrally in the brain — activating melanocortin receptors that directly signal sexual desire, independent of hormone levels. This means it can be effective even when hormonal factors are not the primary driver of HSDD. The two approaches are complementary: hormones address the hormonal foundation; PT-141 addresses the central brain signaling directly.

Is PT-141 FDA-approved and for whom?

Yes. Bremelanotide (Vyleesi) received FDA approval in 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This makes it the only peptide in the longevity and functional medicine space with direct FDA approval for a specific clinical indication relevant to SPOKEmed's patient population. Its approval is specific to premenopausal women; use in postmenopausal women is off-label.

What are the side effects of PT-141?

The most common side effects of PT-141 include nausea (the most frequent, occurring in approximately 40% of users — often manageable with anti-nausea medication), flushing, headache, and transient blood pressure elevation. The blood pressure effect is clinically important — PT-141 is contraindicated in patients with cardiovascular disease. SPOKEmed screens for contraindications and discusses the full risk-benefit profile with patients before prescribing.

Why PT-141 (Bremelanotide / Vyleesi) Matters

PT-141/bremelanotide is the most clinically relevant peptide in SPOKEmed's service context because it has actual FDA approval for an indication — HSDD — directly relevant to the midlife women SPOKEmed serves. Distinguishing it from the majority of unapproved peptides is important for credibility and patient trust.

How Spokmed Company Uses It

PT-141/bremelanotide may be prescribed at SPOKEmed for appropriate patients with HSDD — evaluated within the context of full hormonal assessment and within the scope of its FDA-approved indication. It is one of the few peptide options with regulatory clarity.

Related Services

Related Terms

"PT-141 (Bremelanotide / Vyleesi)" Appears in These Categories

Targeted Peptide Support